B. Jones

发表

Choosing among generalized linear models applied to medical data.

J. Lindsey, B. Jones, J K Lindsey, 1998, Statistics in medicine.

A review of uniform cross-over designs

B. Jones, S. Bate, 2008 .

Design and Analysis of Cross-Over Trials

M. Kenward, B. Jones, 1989 .

A comparison of various estimators of a treatment difference for a multi-centre clinical trial.

D. Teather, J. Lewis, B. Jones, 1998, Statistics in medicine.

The design of multicentre trials

V. Fedorov, B. Jones, 2005, Statistical methods in medical research.

Clinical trials for authorized biosimilars in the European Union: a systematic review

B. Jones, F. Koenig, B. Jilma, 2016, British journal of clinical pharmacology.

Sample Size for Multiple Hypothesis Testing in Biosimilar Development

B. Jones, F. König, B. Jilma, 2018 .

An update on the clinical evidence that supports biosimilar approvals in Europe

B. Jones, F. Koenig, B. Jilma, 2018, British journal of clinical pharmacology.

Trials to assess equivalence: the importance of rigorous methods

J A Lewis, J. Lewis, B. Jones, 1996, BMJ.

Controlling the type I error rate in two‐stage sequential adaptive designs when testing for average bioequivalence

W. Maurer, B. Jones, Ying Chen, 2018, Statistics in medicine.

A proposal for a new PhD level curriculum on quantitative methods for drug development

W. Brannath, X. Paoletti, M. Posch, 2018, Pharmaceutical statistics.

II. Simulation and Retrospective Assessment of Performance of the Proposed FDA metric and the Kullback-Leibler Divergence in Individual Bioequivalence Assessment

V. Fedorov, B. Jones, V. Dragalin, 2001 .

Statistical Issues with the Analysis of Nonrandomized Studies in Comparative Effectiveness Research

R. Willke, B. Jones, J. Alvir, 2011, Journal of managed care pharmacy : JMCP.

Properties of the weighted log‐rank test in the design of confirmatory studies with delayed effects

B. Jones, J. L. Jiménez, V. Stalbovskaya, 2018, Pharmaceutical statistics.

Dose optimisation with simultaneous pharmacokinetic estimation in adaptive clinical trials

B. Bogacka, B. Jones, Kabir Soeny, 2019, Statistical methods in medical research.

Optimizing dose regimens and fixed dose combination ratios in clinical trials

T. Bouillon, B. Bogacka, B. Jones, 2016, Journal of biopharmaceutical statistics.

Bioequivalence and statistics in clinical pharmacology

B. Jones, S. Patterson, 2005 .

Examination of Data, Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using “Real-World Data”

E. Perfetto, R. Willke, P. Subedi, 2011, Journal of Managed Care Pharmacy : JMCP.

Table of Contents Examination of Data , Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using “ Real-World Data ”

E. Perfetto, R. Willke, P. Subedi, 2011 .

Biosimilar Drug Development

B. Jones, J. Mielke, 2020 .

Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study

B. Jones, Morten Bagger, Inga Ludwig, 2022, Pharmaceutical statistics.

Between‐Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial

B. Jones, J. Mielke, L. Benet, 2016, Clinical pharmacology and therapeutics.

Multi-Center Clinical Trials with Random Enrollment: Theoretical Approximations

A. Zhigljavsky, V. Fedorov, B. Jones, 2005 .

Bioequivalence: A Review of Study Design and Statistical Analysis for Orally Administered Products

B. Jones, S. Patterson, 2006 .

The case for cross-over trials in phase III.

J. Lewis, B. Jones, 1995, Statistics in medicine.

A quasilinear regression model for cross-over trials

B. Jones, Ji-qian Fang, Shuqin Yang, 1994 .

The 2 × 2 cross-over trial

M. Kenward, B. Jones, 2014 .

Design of cross-over trials for pharmacokinetic studies

Byron Jones, B. Jones, B. Jones, 1999 .

Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian‐frequentist approach

Heinz Schmidli, Byron Jones, Johanna Mielke, 2018, Biometrical journal. Biometrische Zeitschrift.

Testing Procedures for Claiming Success on at Least k Out of m Hypotheses with an Application to Biosimilar Development

Martin Posch, Franz König, Johanna Mielke, 2021 .

The construction of nearly balanced and nearly strongly balanced uniform cross-over designs

Byron Jones, B. Jones, S. Bate, 2006 .

Alternative approaches to the analysis of binary and categorical repeated measurements.

M. Kenward, B. Jones, 1992, Journal of biopharmaceutical statistics.

The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal

B. Jones, N. Ballarini, M. Schiestl, 2018, The AAPS Journal.

The analysis of categorical data from cross-over trials using a latent variable model.

B Jones, M G Kenward, M. Kenward, 1991, Statistics in medicine.

Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing

L. Benet, B. Jones, K. Carroll, 2021, AAPS PharmSciTech.

The analysis of data from 2 x 2 cross-over trials with baseline measurements.

M. Kenward, B. Jones, Michael G. Kenward, 1987, Statistics in medicine.

Modelling binary data from a three-period cross-over trial.

M G Kenward, M. Kenward, B. Jones, 1987, Statistics in medicine.

A Log‐Linear Model for Binary Cross‐Over Data

Michael G. Kenward, Byron Jones, M. Kenward, 1987 .

Statistical approaches for conducting network meta‐analysis in drug development

Byron Jones, Joseph C Cappelleri, Patrick Moneuse, 2011, Pharmaceutical statistics.

Design and Analysis of Cross-Over Trials, Second Edition

Michael G. Kenward, Byron Jones, M. Kenward, 2003 .

Integrated Data Analysis for Assessing Treatment Effect through Combining Information from All Sources

Christy Chuang-Stein, Byron Jones, Hui Quan, 2017 .

Model based dose personalization in clinical trials

Barbara Bogacka, Byron Jones, Kabir Soeny, 2021, Comput. Methods Programs Biomed..

Cross-over Trials

Byron Jones, B. Jones, 2021, Principles and Practice of Clinical Trials.

Modelling and design of cross-over trials.

B Jones, A N Donev, A. Donev, 1996, Statistics in medicine.

Modeling and Interpreting QTc Prolongation in Clinical Pharmacology Studies

B. Jones, S. Patterson, N. Zariffa, 2005 .

Lessons from meta‐analyses of randomized clinical trials for analysis of distributed networks of observational databases

Christy Chuang-Stein, Byron Jones, Andrew Bate, 2018, Pharmaceutical statistics.

Estimation of the Treatment Difference in Multicenter Trials

A. Zhigljavsky, V. Fedorov, B. Jones, 2004, Journal of biopharmaceutical statistics.

Kullback–Leibler divergence for evaluating bioequivalence

Byron Jones, Vladimir Dragalin, Valerii Fedorov, 2003, Statistics in medicine.

Crossing over to cross‐over trials

Scott Haughie, Byron Jones, B. Jones, 2009 .

Optimal cross-over designs for nonlinear mixed models using a first-order expansion

B. Jones, Jixian Wang, 2009 .

Cross‐over trials in practice: tales of the unexpected

B. Jones, S. Haughie, 2008 .

Re: randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido: north central cancer treatment group protocol N02C3.

B. Jones, S. Haughie, 2008, Journal of the National Cancer Institute.

The analysis of binary and categorical data from crossover trials

B Jones, M G Kenward, B. Jones, 1994, Statistical methods in medical research.

Viewpoint: observations on scaled average bioequivalence

Byron Jones, Scott D Patterson, B. Jones, 2012, Pharmaceutical statistics.

Construction of A-Optimum Cross-Over Designs

Byron Jones, A. N. Donev, A. Donev, 1995 .

Simple models for repeated ordinal responses with an application to a seasonal rhinitis clinical trial.

J. Lindsey, B. Jones, A. Ebbutt, 1997, Statistics in medicine.

Batch‐to‐batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial

B. Jones, B Jones, E Burmeister Getz, 2016, Clinical pharmacology and therapeutics.

Generalized Nonlinear Models for Pharmacokinetic Data

J. Lindsey, B. Jones, J. Wang, 2000, Biometrics.

D-efficient window experimental designs

Barbara Bogacka, Patrick J. Johnson, O. Volkov, 2008 .

Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593‐606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873

W. Brannath, X. Paoletti, M. Posch, 2019, Pharmaceutical statistics.

MODELING PHARMACOKINETIC DATA USING HEAVY-TAILED MULTIVARIATE DISTRIBUTIONS

J. Lindsey, B. Jones, J K Lindsey, 2000, Journal of biopharmaceutical statistics.

A brief review of Phase 1 and Clinical Pharmacology statistics in clinical drug development

Byron Jones, B. Jones, S. Patterson, 2007, Pharmaceutical statistics.

Simulation assessments of statistical aspects of bioequivalence in the pharmaceutical industry

B. Jones, S. Patterson, 2004 .

Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs

F. Bretz, B. Jones, R. Hemmings, 2022, Clinical pharmacology and therapeutics.

Lessons from meta‐analyses of randomized clinical trials for analysis of distributed networks of observational databases

A. Bate, A. Roddam, C. Chuang-Stein, 2018, Pharmaceutical statistics.

A model for cross-over trials evaluating therapeutic preferences.

J. Lindsey, B. Jones, 1996, Statistics in medicine.

THE DESIGN AND ANALYSIS OF MULTICENTRE TRIALS IN THE RANDOM EFFECTS SETTING

Valerii V. Fedorov, Byron Jones, Frank W. Rockhold, 2002 .

Statistical approaches for conducting network meta‐analysis in drug development

J. Cappelleri, B. Jones, J. Roger, 2011, Pharmaceutical statistics.

Bioequivalence

B. Jones, S. Patterson, 2012, International Journal of Pharmaceutical Medicine.

Design and Analysis of Cross-Over Trails.

Michael G. Kenward, Byron Jones, M. Kenward, 1991 .